Intraperitoneal chemotherapy in ovarian cancer: an update.
Based on the poor 5-year survival rates for advanced ovarian cancer, novel therapies are needed. Because ovarian cancer largely is confined to the peritoneal cavity for much of its natural history, the intraperitoneal administration of chemotherapy is a biologically rationale and novel approach to the delivery of chemotherapy. Interest in intraperitoneal therapy as first-line therapy has been rekindled by three large randomized clinical trials, which have demonstrated improved median overall survival rates. This article reviews these trials and addresses areas of concern and the need for additional trials.
Runowicz
Carolyn D
CD
Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington, CT 05030, USA. crunowicz@uchc.edu
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents